ライフサイエンスコーパス: podoplanin

1 platelets promotes clustering of CLEC-2 and Podoplanin.

2 alitogenic molecular players like GM-CSF and podoplanin.

3 uronan (HA) receptor, is a novel partner for podoplanin.

4 cific CD44 antibody induced corecruitment of podoplanin.

5 hodocytin and the tumor cell surface protein podoplanin.

6 elial growth factor receptor 3 (VEGFR-3) and podoplanin.

7 of lymphatic endothelium such as LYVE-1 and podoplanin.

8 34, VE-cadherin, CD51/61, CD105, LYVE-1, and podoplanin.

9 termined by immunohistochemical staining for podoplanin.

10 en isolated via FACS-sorting with LYVE-1 and PODOPLANIN.

11 tified by staining immunohistochemically for podoplanin.

12 fty-one tumor specimens stained positive for podoplanin (33 high expression, 47 medium expression, 71

13 Levels of podoplanin (a marker of lymphatic vessels), VEGFC, and V

14 eficiency in CLEC-2 as well as inhibition of podoplanin, a ligand of CLEC-2, was associated with redu

15 We have shown that podoplanin, a lymphatic endothelial marker, is highly ex

16 We hypothesized that podoplanin, a sialomucin-like glycoprotein, increases th

17 Here, we uncover a new role for podoplanin, a transmembrane glycoprotein closely associa

18 bear its cognate Tn-glycopeptide epitope in podoplanin, also called OTS8.

19 Mesothelial cells expressed podoplanin and ALCAM.

20 al role in vascular inflammation through the podoplanin and collagen/fibrin receptors, C-type-lectin-

21 galectin-8-dependent crosstalk among VEGF-C, podoplanin and integrin pathways plays a key role.

22 Immunohistochemical staining against podoplanin and intratumoral platelet aggregates was perf

23 on of the lymphatic endothelial cell markers podoplanin and lymphatic vessel endothelial hyaluronan r

24 t Ebp1 has a key role in the upregulation of podoplanin and may contribute to oral tumorigenesis.

25 llows local inflammation and upregulation of podoplanin and platelet activation.

26 ICs expressed caveolin-1, podoplanin and receptor for advanced glycation end-produ

27 which CLEC-2 signaling promotes adhesion to Podoplanin and regulation of Podoplanin signaling, there

28 tent induction of the lymphatic marker genes podoplanin and vascular endothelial growth factor recept

29 The LYVE-1(-) lymphatic gaps expressed podoplanin and VE-cadherin but not alphaSMA or FOXC2.

30 n atypical phenotype, with the expression of podoplanin and VEGF receptor 3 (VEGFR-3) but not of LYVE

31 of systemic sclerosis patients, and CD34(-), podoplanin(+), and CD90(+) fibroblasts appear.

32 d surface (CD44, CD54, CD115, CD140a, CD196, podoplanin) and functional markers (interferon-y, interl

33 express surfactant proteins, ABCA3, GM-CSF, podoplanin, and caveolin mRNA after 7 days, temporal ind

34 receptor, C-type lectin 2, the receptor for podoplanin, and Fc receptor gammaII A, a low-affinity re

35 , semaphorin 3F, neuropilin 1, neuropilin 2, podoplanin, and LYVE-1 by quantitative (real-time) rever

36 ndothelial cell marker, Flt4/VEGFR3, but not podoplanin, and they have hyaluronan-binding ability.

37 ations of myofibroblasts, strongly expressed podoplanin, and were enriched for Wnt ligand signaling.

38 antly patterned at embryonic (E) day 10.5 in podoplanin- and CLEC-2-deficient mice, preceding the for

39 othelial hyaluronate receptor 1 (LYVE-1) and podoplanin antibodies.

40 confirmed in normal mouse tissues with anti-podoplanin antibody 8.1.1.

41 esults also suggest the potential utility of podoplanin as a mechanism-based biomarker for rapid scre

42 We report podoplanin as a novel component of invadopodia-associate

43 These data identify T1alpha/podoplanin as a novel critical player that regulates dif

44 els was analyzed immunohistochemically using podoplanin as a specific lymphatic endothelial marker in

45 he multivariate analysis using histology and podoplanin as cofactors, podoplanin was the only indepen

46 e expression of lymphatic markers Prox-1 and podoplanin as early as 8 h p.i., and a paracrine effect

47 entify lymphatic vessels by using LYVE-1 and podoplanin as specific markers for lymphatic vascular en

48 antibody D2-40 specifically recognized human podoplanin, as assessed by enzyme-linked immunosorbent a

49 To induce deletion of podoplanin at the 2-cell stage, we generated a podoplani

50 oblast mechanics through genetic deletion of podoplanin attenuates T cell activation.

51 We show that previously reported podoplanin-based LEC heterogeneity is associated with di

52 ated by its only known physiological ligand, podoplanin, being an integral membrane protein.

53 ligand by lymphoid tissue inducer cells and podoplanin by T zone stroma are temporally linked, and t

54 arrow, by a population of IL-17RA-expressing podoplanin(+)CD31(-) stromal cells, a profile associated

55 CD73(+)CD90(+) and podoplanin + CD36+ cells expressed markers consistent wi

56 enotype, in culture CD73(+)CD90(+) cells and podoplanin(+)CD36(+) cells underwent phenotypic converge

57 ther suggested cultured pMSCs originate from podoplanin(+)CD36(+) cells.

58 cells, CD146(+)CD271(+) perivascular cells, podoplanin(+)CD36(+) stromal cells, and CD26(+)CD90(+) m

59 Podoplanin-CD44s interaction was demonstrated both by co

60 ng markers of tendon inflammation, including podoplanin, CD90, phosphorylated signal transducer and a

61 ory phenotype of AT and AR cells, regulating podoplanin, CD90, signal transducer and activator of tra

62 Podoplanin(+) cells also expressed high levels of lympha

63 We further confirmed that podoplanin(+) cells exist in small numbers in BM and per

64 Next, to evaluate the potential of podoplanin(+) cells for the formation of new lymphatic v

65 These podoplanin(+) cells highly express markers for lymphatic

66 ture-isolated or freshly isolated BM-derived podoplanin(+) cells into wound and tumor models.

67 Among these cells, podoplanin(+) cells were isolated by magnetic-activated

68 provide compelling evidence that BM-derived podoplanin(+) cells, a previously unrecognized cell type

69 These hPSC-derived LYVE-1(+)PODOPLANIN(+)cells showed a pure committed LEC phenotype

70 We suggest podoplanin-CLEC-2 as a novel anti-inflammatory axis regu

71 In carcinoma cells, CD44 and podoplanin colocalize at cell surface protrusions.

72 scular endothelium hyaluronate receptor) and podoplanin contribute to lymphatic vessels in full-thick

73 the presence of lymphatic endothelium using podoplanin (D2-40 antibody) and blood vessel endothelium

74 d in tumor-associated lymphangiogenesis, and podoplanin deficiency results in congenital lymphedema a

75 ly reduced in EHC T-syn(-/-) lymphatics, and podoplanin-deficient mice developed blood-filled lymphat

76 Podoplanin downregulation in SCC cells impairs invadopod

77 rdinately up-regulated together with that of podoplanin during progression to highly aggressive SCCs

78 Podoplanin engagement is strictly required for BAT expan

79 tin-like receptor-2 (CLEC-2) on platelets by podoplanin exposed to the vasculature following breachin

80 CLEC-2 receptors by the transmembrane ligand podoplanin expressed by lymphatic endothelial cells.

81 for podoplanin or molecules associated with podoplanin expressing stroma in the effective segregatio

82 in a marked reduction of lung metastasis of podoplanin-expressing B16F10 cells.

83 novel therapeutic strategy in patients with podoplanin-expressing cancer.

84 ciency is associated with reduced numbers of podoplanin-expressing macrophages despite increased cyto

85 on, IFN-gamma release enhanced the number of podoplanin-expressing monocytes and Kupffer cells in the

86 lar helper (Tfh) cell lineages, and included podoplanin-expressing T cells within lymphoid aggregates

87 lp areas, where they associate directly with podoplanin-expressing T zone stromal cells.

88 IL-27 inhibited the differentiation of podoplanin-expressing Th17 cells, and an increased numbe

89 confirm whether testing for PD-L1, EGFR, and podoplanin expression aids in cutaneous squamous cell ca

90 In a high-density culture condition, podoplanin expression can be triggered at both mRNA and

91 terfering RNA-mediated inhibition of T1alpha/podoplanin expression decreased lymphatic endothelial ce

92 In conclusion, high podoplanin expression in primary brain tumors induces pl

93 -six (37%) of the 150 OPL patients exhibited podoplanin expression in the basal and suprabasal layers

94 erve as a transcriptional activator to drive podoplanin expression in the malignant progression.

95 m of DVT, whereby CLEC-2 and upregulation of podoplanin expression in the venous wall trigger thrombu

96 Thromboinflammation induced ectopic podoplanin expression in vascular endothelial cells or m

97 Podoplanin expression is associated with VTE in patients

98 Ebp1 downregulation significantly reduced podoplanin expression levels in OSCC cells with a decrea

99 However, mechanisms regulating podoplanin expression remain elusive.

100 High podoplanin expression was associated with an increased r

101 Podoplanin expression was determined in 150 OPL patients

102 was correlated with elevated HIF-1alpha and podoplanin expression whilst expression of inflammatory

103 postnatal development, in part by regulating podoplanin expression.

104 it led to significant decreases in IL-6 and Podoplanin expression.

105 sed risk of VTE (hazard ratio for high vs no podoplanin expression: 5.71; 95% confidence interval, 1.

106 We generated a human podoplanin-Fc fusion protein and found that the commerci

107 nths, including T-cell rich zones containing podoplanin + fibroblastic reticular stromal cells and B-

108 sentery and omentum containing resident gp38/podoplanin(+) fibroblastic reticular cells.

109 doplanin at the 2-cell stage, we generated a podoplanin(fl/fl) mouse crossed to a PGK-Cre mouse.

110 outinely used lymphatic endothelial marker), podoplanin, Flt4/VEGFR3, Sca-1, CD11b, or F4/80 and were

111 sion of another lymphatic-specific gene, the podoplanin gene, but does inhibit the expression of VEGF

112 Poorly studied podoplanin (gp38)-negative CD31(-) LNSCs showed similari

113 Thus, podoplanin has a key role in the regulation of invadopod

114 , research into the biological importance of podoplanin has been hampered by the lack of a generally

115 rotein rhodocytin and the endogenous protein podoplanin have been identified as ligands.

116 ased lymphatic vessel density as measured by podoplanin immunohistochemistry (P < 0.001) and whole mo

117 and lymphatic vessel density as measured by podoplanin immunohistochemistry and whole mount skin ana

118 and type I cells and/or type I cell-specific podoplanin immunoreactivity.

119 ng the functional role of CAF-like cells and podoplanin in CNT tumorigenic process.

120 pose of this study is to determine a role of podoplanin in predicting oral cancer development in pati

121 , primary dermal fibroblasts readily express podoplanin in response to the inflammatory stimuli tumor

122 The level of podoplanin in the IVC increased after 48 hours of stenos

123 These findings suggest a potential role of podoplanin in tumor progression, and they also identify

124 this study, we examined the role of T1alpha/podoplanin in vascular development and the effects of ge

125 f CLEC-2, a natural ligand/receptor for Gp38/Podoplanin, in the formation of the lymphatic vasculatur

126 In the bloodstream, podoplanin induces platelet activation by binding to CLE

127 stratified by considering both histology and podoplanin information.

128 Our results support a role for CD44-podoplanin interaction in driving tumor cell migration d

129 Blocking CLEC-2-podoplanin interaction may be a novel therapeutic strate

130 nificantly inhibited, suggesting that CLEC-2-podoplanin interaction stimulates cancer-associated thro

131 Podoplanin is a transmembrane glycoprotein up-regulated

132 T1alpha/podoplanin is also expressed in the basal epidermis of n

133 A membrane protein, podoplanin is expressed in certain types of cancer cells

134 T1alpha/podoplanin is first expressed at around E11.0 in Prox1-p

135 Podoplanin is frequently expressed in OPL.

136 Podoplanin is highly expressed in human cancers.

137 ucin-type transmembrane glycoprotein T1alpha/podoplanin is predominantly expressed by lymphatic endot

138 The mucin-type glycoprotein podoplanin is specifically expressed by lymphatic but no

139 The presence of intraocular LYVE-1(+)/podoplanin(+) lymphatic vessels was significantly associ

140 Intraocular LYVE-1(+) and podoplanin(+) lymphatic vessels were detected in 7 of 10

141 ension revealed no intraocular LYVE-1(+) and podoplanin(+) lymphatic vessels.

142 for vascular and lymphatic markers including podoplanin, lymphatic vessel endothelial hyaluronan rece

143 ression of lymphatic markers such as Prox-1, podoplanin, Lyve-1, VEGF receptor-2, and VEGF receptor-3

144 elial cells based upon reduced expression of podoplanin, LYVE1 and VEGFR3.

145 Together with histology, podoplanin may serve as a powerful biomarker to predict

146 T1alpha/podoplanin(-/-) mice die at birth due to respiratory fai

147 Clusters of CLEC-2-bound Podoplanin migrate rapidly to the center of the platelet

148 , they begin expressing the lymphatic marker podoplanin, migrate away from the CV, and form the lymph

149 othelial hyaluronan receptor-1 (LYVE-1), and podoplanin mRNA and contained more lymphatic vessels tha

150 promoter to result in a dramatic increase of podoplanin mRNA and protein.

151 of oral cancer than did those whose OPL was podoplanin negative (P = .0002).

152 Treatment of animals with an anti-podoplanin neutralizing antibody resulted in development

153 own experiments showed that an expression of podoplanin on CAF-like cells is essential for their effe

154 lectin receptor 2 (CLEC-2) on platelets with Podoplanin on lymphatic endothelial cells initiates plat

155 Nestin-Cre-driven deletion of podoplanin on neural progenitors also caused widespread

156 od, Tamura et al reveal a novel function for podoplanin on periarteriolar stromal cells in the bone m

157 Finally, we show that the appearance of podoplanin on T zone stroma in development is associated

158 up-regulate the expression of both CCL21 and podoplanin on T zone stroma of RAG-deficient mice.

159 Abs of the transmembrane mucin-type protein podoplanin on T zone stroma, although expression at othe

160 We propose a novel role for podoplanin on the neuro-epithelium, which interacts with

161 e not all lymphatic progenitor cells express podoplanin or Lyve-1, which are acquired with advancing

162 and our data point to a significant role for podoplanin or molecules associated with podoplanin expre

163 idence interval = 1.24-5.33, P = 0.011), and podoplanin (OR = 2.33, 95% confidence interval = 1.00-5.

164 ls consistently identified the expression of podoplanin (Overall Survival (OS)/Disease-specific Survi

165 imbalances, polysomy, p53, overexpression of podoplanin, p63 or epidermal growth factor receptor (EGF

166 17 (IL-17) and on the cell surface molecule Podoplanin (Pdp), which was expressed on Th17 cells, but

167 Tumor expression of tissue factor (TF) and podoplanin (PDPN) each positively correlated with VTE, a

168 report here that Src utilizes Cas to induce podoplanin (Pdpn) expression to promote tumor cell migra

169 those aged >40 years, accompanied by reduced podoplanin (PDPN) expression, increased versican express

170 ion tissue or fluid on the basis of CD31 and podoplanin (PDPN) expression.

171 Podoplanin (Pdpn) is a small, transmembrane glycoprotein

172 Podoplanin (PDPN) is a transmembrane receptor that affec

173 Podoplanin (PDPN) is intensely expressed on the podocyte

174 Here we demonstrate that podoplanin (PDPN) regulates actomyosin contractility in

175 city of lymph nodes is maintained in part by podoplanin (PDPN) signalling in stromal fibroblastic ret

176 PODOPLANIN (PDPN), a transmembrane protein expressed on

177 Herein, we report that podoplanin (PDPN), the ligand of C-type lectin-like rece

178 hibitor of metalloproteinases 1 (Timp1), and podoplanin (Pdpn), were significantly FGF-2 dependent fo

179 ogressive differentiation of a population of podoplanin (pdpn)-positive stromal cells into a network

180 omal scaffolds that display the glycoprotein podoplanin (PDPN).

181 r cells mediated cell survival by modulating podoplanin (PDPN).

182 a role for the transmembrane O-glycoprotein podoplanin (PDPN, also known as gp38 and T1alpha) in mai

183 Podoplanin (PDPN, also known as Gp38) is highly expresse

184 d fibroblast markers and adhesion molecules (podoplanin [PDPN], ICAM-1, and VCAM-1) and secretion of

185 Patients with OPL that was podoplanin positive had significantly higher incidence o

186 and suprabasal layers and were classified as podoplanin positive.

187 ructure (TLS)-like aggregates, and increased podoplanin-positive cancer-associated fibroblasts (CAFs)

188 ctant protein expression and accumulation of podoplanin-positive cells at the wound edge.

189 es the differentiation of lung stroma toward podoplanin-positive CXCL12-expressing cells that allow f

190 CAS more than 4, as well as rare staining of podoplanin-positive lymphatic vessels within acutely inf

191 Podoplanin-positive primary glioblastoma cells induced a

192 Patients with podoplanin-positive tumors had lower peripheral blood pl

193 Podoplanin positivity was more frequent in older patient

194 he cytoplasm to the nucleus and binds to the podoplanin promoter to result in a dramatic increase of

195 ured endothelial cells indicate that T1alpha/podoplanin promotes cell adhesion, migration and tube fo

196 Importantly, we also show that podoplanin promotes directional persistence of motility

197 Here we show that podoplanin promotes tumorigenesis of oral squamous cell

198 st of the OSCC cell lines have no detectable podoplanin protein in low-density cultures.

199 21 mice promoted the development of LYVE-1(+)podoplanin(+)Prox-1(+) vessels in the thyroid.

200 collagen receptor glycoprotein VI (GPVI) and podoplanin receptor C-type lectin-like receptor 2 (CLEC2

201 Early podoplanin recruitment to invadopodia is dependent on li

202 bition of the interaction between CLEC-2 and podoplanin regulates immune cell infiltration and the in

203 Finally, we demonstrate that podoplanin regulates invadopodia maturation by acting up

204 cade or platelets, such as tissue factor and podoplanin, respectively.

205 rafts, whereas ezrin/moesin proteins mediate podoplanin ring assembly.

206 that C-type lectin-like receptor 2 (CLEC-2)-podoplanin signaling regulates the cell surface mechanic

207 tes adhesion to Podoplanin and regulation of Podoplanin signaling, thereby contributing to lymphatic

208 Podoplanin staining intensity was associated with increa

209 Furthermore, podoplanin staining on stromal cells was more diffuse, a

210 Immunofluorescence indicated that podoplanin(+) stromal cells in the red pulp were the pri

211 vasculature and the differentiation of Gp38/Podoplanin(+) stromal cells, we investigated the role of

212 vascular marker, CD31, and lymphatic marker, podoplanin, suggesting a role for macrophages in angioge

213 We found that Lyve1 and Podoplanin, two established markers of LVs, were markedl

214 during sepsis, suggesting that activation of podoplanin underlies the anti-inflammatory action of pla

215 on enhanced these malignant features through podoplanin upregulation both in vitro and in vivo.

216 iferating lymphatic vessels, with LYVE-1 and podoplanin used as specific lymphatic endothelial marker

217 lso seen in platelets adhered to immobilized Podoplanin using direct stochastic optical reconstructio

218 embranes from patients did not show LYVE-1(+)podoplanin(+) vessels, suggesting the lack of lymphangio

219 that, in addition to lymphatic endothelium, podoplanin was also expressed by peritoneal mesothelial

220 Podoplanin was also strongly expressed by granulosa cell

221 Podoplanin was expressed in the IVC wall, where it was l

222 Although podoplanin was primarily absent from normal human epider

223 The level of O-glycoprotein podoplanin was significantly reduced in EHC T-syn(-/-) l

224 using histology and podoplanin as cofactors, podoplanin was the only independent factor for oral canc

225 g supported lipid bilayers containing mobile Podoplanin, we further show that activation of Src and S

226 he GPVI ligand collagen and the CLEC2 ligand podoplanin were constitutively present in the lung, wher

227 ceptor 2 (CLEC-2), and its endogenous ligand podoplanin, which are the focus of this review.

228 CLEC-2 activation by its endogenous ligand, podoplanin, which is expressed on the developing neural

229 -2 is activated by the transmembrane protein podoplanin, which is found outside of the vasculature an